ASCO 2022 | The efficacy of ICIs for melanoma in-transit nodal metastases with or without nodal metastasis
Roger Olofsson Bagge, MD, PhD, Gothenburg University, Gothenburg, Sweden, discusses a mutlicenter retrospective cohort study investigating the efficacy of immune checkpoint inhibitors (ICI) for melanoma in-transit with or without nodal metastases. Patients had been treated with either a PD-1 inhibitor (nivolumab or pembrolizumab) and/or ipilmumab, a CTLA-4 inhibitor. Response rates, progression-free survival, melanoma-specific survival (MSS) and overall-survival were assessed. A 56% overall response rate (ORR) was achieved, the complete response (CR) rate was 36% and progressive disease (PD) rate was 32%. A median PFS of 10 months was observed and median MSS was not reached. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
